No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Indirect comparisons using predicted RRs for fingolimod in an alternative trial population were significantly greater than 1 for all analyses versus DMF in a pooled DEFINE and CONFIRM population and for analyses versus teriflunomide 7 and 14 mg in a TEMSO population (with the exception of the clinical composite for the teriflunomide 14 mg comparison in which only a positive trend was observed).

also in 11,005 other papers